SBIR-STTR Award

Discovery Of Compounds To Inhibit Cancer Emt Genes In Order To Target Metastasis
Award last edited on: 6/7/11

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$146,030
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Stephen Felder

Company Information

NuvoGen Research LLC (AKA: Neogen LLC)

2602 Avenida De Posada Po Box 64326
Tucson, AZ 85728
   (520) 270-5209
   sfelder@nuvogenresearch.com
   www.nuvogenresearch.com
Location: Single
Congr. District: 02
County: 

Phase I

Contract Number: 1R43CA141815-01
Start Date: 7/1/09    Completed: 4/30/10
Phase I year
2009
Phase I Amount
$146,030
The overall objective of the work proposed in this grant is to find novel drugs that help to prevent metastasis. In Phase I, newly available natural product extracts will be tested to find compounds that specifically target genes that are critical for the Epithelial to Mesenchymal Transition (EMT) in several different tumor cell models. Many lines of evidence suggest that tumor cells become metastatic through the EMT process. Transcription of a set of genes is altered in EMT, and the alterations correlate with metastatic potential. A drug that can block these gene expression changes may directly target metastasis. In addition, evidence suggests that EMT may allow tumor cells to become drug resistant. A quantitative high-throughput gene chip assay, ArrayPlate, will test extracts for their effect on the EMT gene expression signature. The extracts are derived from Sonoran desert plants and associated microorganisms recently isolated by the Southwest Center for Natural Product Research and Commercialization, at the University of Arizona. Phase II will follow up on reconfirmed hit fractions identified in Phase I. Fractions will be further separated and retested to attempt to isolate and identify active compounds. Compounds with sufficient activity will be tested in in vitro EMT models and in in vivo models of metastatic cancer. Novel therapeutics that target cancer EMT and so blocking metastasis may be useful in treating particular types of cancer especially in combination with other drug regimens, and may help reduce drug resistance.

Public Health Relevance:
Metastasis, the ability of cells to leave a tumor site and spread to other sites, is the major cause of death in cancer. Recent evidence suggests that there is one general mechanism of genetic reprogramming that is used by all tumors in becoming metastatic. The goal of this grant is to discover a new class of cancer drugs that will not stop the growth of tumor cells, but instead directly block metastasis, by interfering with this genetic reprogramming mechanism.

Public Health Relevance Statement:
Relevance Metastasis, the ability of cells to leave a tumor site and spread to other sites, is the major cause of death in cancer. Recent evidence suggests that there is one general mechanism of genetic reprogramming that is used by all tumors in becoming metastatic. The goal of this grant is to discover a new class of cancer drugs that will not stop the growth of tumor cells, but instead directly block metastasis, by interfering with this genetic reprogramming mechanism.

Project Terms:
Active Follow-up; Alcohol, Methyl; Anti-Cancer Agents; Anti-Tumor Agents; Anti-Tumor Drugs; Antineoplastic Agents; Antineoplastic Drugs; Antineoplastics; Antiproliferative Agents; Antiproliferative Drugs; Applications Grants; Arizona; Assay; Bioassay; Biologic Assays; Biological Assay; Biological Factors; Breast; Cancer Drug; Cancer Model; Cancer Patient; Cancer of Lung; CancerModel; Cancers; Carbinol; Carcinoma; Cause of Death; Cell Death; Cell Line; Cell Lines, Strains; Cell model; CellLine; Cells; Cellular model; Chemotherapeutic Agents, Neoplastic Disease; Chloroform; DNA; Deoxyribonucleic Acid; Development; Disease; Disorder; Disseminated Malignant Neoplasm; Dose; Drug resistance; Drugs; Embryo; Embryonic; Epithelial; Epithelial Neoplasms, Malignant; Epithelial Tumors, Malignant; Factor, Biologic; Gene Chips; Gene Expression; Gene Expression Chip; Gene Expression Profile; Gene Targeting; Gene Transcription; Generalized Growth; Genes; Genetic; Genetic Transcription; Goals; Grant; Grant Proposals; Grants, Applications; Growth; Human Genome; In Vitro; Left; Malignant Cell; Malignant Neoplasms; Malignant Tumor; Malignant Tumor of the Lung; Malignant neoplasm of lung; Medication; Mesenchymal; Metastasis; Metastasize; Metastatic Cancer; Metastatic Malignant Neoplasm; Metastatic Neoplasm; Metastatic Tumor; Metastatic to; Methane, trichloro-; Methanol; Microorganisms, General; Modeling; Natural Products; Neoplasm Metastasis; Ovarian; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Plants; Plants, General; Process; Protocols, Treatment; Pulmonary Cancer; Pulmonary malignant Neoplasm; RGM; RNA Expression; Regimen; Reporting; Research; Sampling; Secondary Neoplasm; Secondary Tumor; Site; Solid Neoplasm; Solid Tumor; Targetings, Gene; Technology; Testing; Tissue Growth; Transcription; Transcription, Genetic; Treatment Protocols; Treatment Regimen; Treatment Schedule; Trichloromethane; Tumor Cell; Tumor Cell Migration; Tumor-Specific Treatment Agents; Universities; Wood Alcohol; Work; anticancer agent; anticancer drug; cancer cell; cancer metastasis; cancer type; commercialization; cultured cell line; disease/disorder; drug resistant; drug/agent; epithelial carcinoma; epithelial to mesenchymal transition; follow-up; gene expression signature; in vivo Model; lung cancer; malignancy; microorganism; necrocytosis; neoplasm/cancer; neoplastic cell; new therapeutic target; novel; ontogeny; prevent; preventing; public health relevance; resistance to Drug; resistant to Drug; response; transcriptome; tumor

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----